Literature DB >> 14509051

[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].

Mirijam Fric1, Gerd Laux.   

Abstract

Elevations in prolactin plasma concentration occur with antipsychotics due to their dopamine D2 receptor antagonism. Hyperprolactinemia may be associated with both acute (galactorrhea, amenorrhea, decreased libido etc.) and chronic (predisposition to osteoporosis and cardiovascular disease) treatment emergent effects in both men and women associated with apparently impaired compliance. The aim of our study was to investigate these supposed effects regarding clinically relevant endocrinologic symptoms under routine treatment conditions with newer, atypical antipsychotics. Our findings confirm that amisulpride frequently leads to a remarkable elevation of prolactin plasma concentration, same--in minor degree--for risperidone. Under treatment with quetiapine and olanzapine just temporary elevated prolactin levels were registered. However, no correlation between prolactin levels and dosage could be found. In females treated with amisulpride acute hormonal side effects were seen in a clinically relevant manner. Features of illness itself, stress factors, concomitant medication or other patient's conditions are supposed to be relevant factors for acute endocrine symptomatology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14509051

Source DB:  PubMed          Journal:  Psychiatr Prax        ISSN: 0303-4259


  3 in total

1.  Osteoporosis after combined use of a neuroleptic and antidepressants.

Authors:  Gert Laekeman; Lieven Zwaenepoel; Johan Reyntens; Marc de Vos; Minne Casteels
Journal:  Pharm World Sci       Date:  2008-06-24

2.  Amisulpride withdrawal akathisia responding to aripiprazole with propranolol in first-onset psychosis: a case report.

Authors:  Hae-Jung Yang; Seung-Gon Kim; Eun Hyun Seo; Hyung-Jun Yoon
Journal:  BMC Psychiatry       Date:  2022-01-29       Impact factor: 3.630

3.  Pharmacological causes of hyperprolactinemia.

Authors:  Daria La Torre; Alberto Falorni
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.